IWV News
DraftKings Shares Are Falling Today – Here’s Why
Analysts from Stifel, JPMorgan and Guggenheim have slashed their price target on Draftkings ahead of its Q4 earnings due Monday.
DraftKings Shares Are Falling Today – Here’s Why
Analysts from Stifel, JPMorgan and Guggenheim have slashed their price target on Draftkings ahead of its Q4 earnings due Monday.
Intuitive is now part of 34 global volunteers chosen by the agency to track Artemis II.
Culper Research said it has little faith in T1’s management, nor the company’s disclosures and financial reporting and said that shares are headed far lower.
The company recently expanded on its Sanofi partnership to include its Matrix-M adjuvant in Sanofi’s pandemic influenza vaccine candidate program and renegotiated its deal with Takeda in a bid to grow revenues from the latter's activities involving Nuvaxovid vaccine in Japan.
The company now expects revenue from Ibsrela to be between $270 million and $275 million for the full year.
Jackson added that he was long on the stock, while highlighting that the biotech company’s balance sheet is solid.
The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.
The company said that anaphylaxis or a severe allergic reaction was reported in seven participants in the open-label study evaluating Nomlabofusp in participants with Friedreich’s ataxia.